CA2246482C - Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht [1,2-b]-1,4-oxazines disubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht [1,2-b]-1,4-oxazines disubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDF

Info

Publication number
CA2246482C
CA2246482C CA002246482A CA2246482A CA2246482C CA 2246482 C CA2246482 C CA 2246482C CA 002246482 A CA002246482 A CA 002246482A CA 2246482 A CA2246482 A CA 2246482A CA 2246482 C CA2246482 C CA 2246482C
Authority
CA
Canada
Prior art keywords
ppm
formula
compound
trans
previously defined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002246482A
Other languages
English (en)
French (fr)
Other versions
CA2246482A1 (fr
Inventor
Jean-Louis Peglion
Jean-Christophe Harmange
Mark Millan
Francoise Lejeune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CA2246482A1 publication Critical patent/CA2246482A1/fr
Application granted granted Critical
Publication of CA2246482C publication Critical patent/CA2246482C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002246482A 1997-09-01 1998-08-31 Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht [1,2-b]-1,4-oxazines disubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Expired - Fee Related CA2246482C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR97.10852 1997-09-01
FR9710852A FR2767825A1 (fr) 1997-09-01 1997-09-01 Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
CA2246482A1 CA2246482A1 (fr) 1999-03-01
CA2246482C true CA2246482C (fr) 2002-11-26

Family

ID=9510643

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002246482A Expired - Fee Related CA2246482C (fr) 1997-09-01 1998-08-31 Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht [1,2-b]-1,4-oxazines disubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Country Status (18)

Country Link
US (1) US6025356A (https=)
EP (1) EP0899267B1 (https=)
JP (1) JP4417451B2 (https=)
CN (1) CN1088064C (https=)
AT (1) ATE229513T1 (https=)
AU (1) AU740928C (https=)
BR (1) BR9803933A (https=)
CA (1) CA2246482C (https=)
DE (1) DE69810034T2 (https=)
DK (1) DK0899267T3 (https=)
ES (1) ES2189108T3 (https=)
FR (1) FR2767825A1 (https=)
HU (1) HU226059B1 (https=)
NO (1) NO311218B1 (https=)
NZ (1) NZ331637A (https=)
PL (1) PL194533B1 (https=)
PT (1) PT899267E (https=)
ZA (1) ZA987963B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
EP1534679A4 (en) * 2002-08-30 2007-06-06 Biostratum Inc INHIBITORS OF POST-AMADORI ADVANCED GLYCATION ENDPRODUCTS
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
FR2906249B1 (fr) * 2006-09-26 2008-12-19 Servier Lab Composes tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2098511A1 (en) 2008-03-07 2009-09-09 Solvias AG Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring
CN102131790A (zh) * 2008-06-27 2011-07-20 H.隆德贝克有限公司 新型苯酚型和儿茶酚型胺及其前药

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420480A (en) * 1981-11-20 1983-12-13 Merck & Co., Inc. Hexahydronaphth[1,2-b]-1,4-oxazines
CA1204745A (en) * 1981-11-20 1986-05-20 Merck Co. Hexahydronaphth (1,2-b) -1,4 -oxazines
US4540691A (en) * 1984-04-13 1985-09-10 Nelson Research & Development Co. Dopamine agonists and use thereof
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
WO1991019719A1 (en) * 1990-06-15 1991-12-26 Whitby Research, Inc. Substituted naphthoxazines useful as dopaminergics

Also Published As

Publication number Publication date
DK0899267T3 (da) 2003-03-10
HU226059B1 (en) 2008-04-28
CN1222516A (zh) 1999-07-14
ZA987963B (en) 1999-03-04
CA2246482A1 (fr) 1999-03-01
DE69810034T2 (de) 2003-08-14
ES2189108T3 (es) 2003-07-01
DE69810034D1 (de) 2003-01-23
PT899267E (pt) 2003-04-30
HUP9801951A2 (hu) 2000-02-28
NO984007D0 (no) 1998-08-31
BR9803933A (pt) 2001-04-24
NZ331637A (en) 1999-07-29
HUP9801951A3 (en) 2000-04-28
EP0899267A1 (fr) 1999-03-03
AU740928C (en) 2002-05-16
PL328285A1 (en) 1999-03-15
ATE229513T1 (de) 2002-12-15
AU8302498A (en) 1999-03-11
HU9801951D0 (en) 1998-11-30
HK1020340A1 (en) 2000-04-14
JPH11130759A (ja) 1999-05-18
NO984007L (no) 1999-03-02
CN1088064C (zh) 2002-07-24
FR2767825A1 (fr) 1999-02-26
JP4417451B2 (ja) 2010-02-17
NO311218B1 (no) 2001-10-29
PL194533B1 (pl) 2007-06-29
EP0899267B1 (fr) 2002-12-11
AU740928B2 (en) 2001-11-15
US6025356A (en) 2000-02-15

Similar Documents

Publication Publication Date Title
CA2207835C (fr) Nouveaux derives du 3-(piperid-4-yl) 1,2-benzisoxazole et du 3-(piperazin-4-yl) 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP0506539B1 (fr) Amides alkyl hétérocycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CA2593613A1 (fr) Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2797874A1 (fr) Nouveaux derives de la pyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2300424B1 (fr) Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
CA2246482C (fr) Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht [1,2-b]-1,4-oxazines disubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0906912B1 (fr) Nouveaux composés de l'indanol, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0452204B1 (fr) Nouveaux dérivés du 3-aminochromane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0894796B1 (fr) Imidazolines substituées par un noyau hétérocyclique, alpha-2 antaginistes
EP1828125B1 (fr) Derives d'arylpiperazine et leur utilisation comme ligands selectifs du recepteur d3 de la dopamine
EP0718299B1 (fr) Ethers d'oximes tricycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JP2744224B2 (ja) ビス−アザ−二環式抗不安薬の製法
JPH11130759A5 (https=)
EP0773223B1 (fr) Nouveaux composés tétracycliques de la 1,4-oxazine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP1106608B1 (fr) Nouveaux dérivés (dihydro)benzoxaziniques et (dihydro)benzothiaziniques substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP1905775B1 (fr) Composés tétracycliques, leur procédé de préparation, les compositions pharmaceutiques qui les contiennent et leur utilisation comme ligands des récepteurs dopaminergiques.
WO2009022063A2 (fr) Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2918368A1 (fr) Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HK1020340B (en) New disubstituted trans-3,4,4a,5,6,10b-hexahydro-2h-naphth (1,2-b)-1,4-oxazines, a process for their preparation and pharmaceutical compositions containing them
FR2918371A1 (fr) Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20010006863A (ko) 신규한 벤조[3,4]사이클로부타[1,2-ｃ]피롤 화합물,이것의 제조 방법 및 이것을 함유하는 약제학적 조성물
FR2523130A1 (fr) Nouveaux derives de la n-dihydrothiazolyl-3-quinoleine carboxamide, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130903